| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-28904SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NLS932AF405 | |||
| Alexa Fluor 488 | NLS932AF488 | |||
| Alexa Fluor 647 | NLS932AF647 | |||
| Alexa Fluor 700 | NLS932AF700 | |||
| Biotin | NLS932B | |||
| DyLight 405 | NLS932V | |||
| DyLight 488 | NLS932G | |||
| DyLight 550 | NLS932R | |||
| DyLight 650 | NLS932C | |||
| FITC | NLS932F | |||
| HRP | NLS932H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-81601SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2068SS | |||
| Azide and BSA Free | NBP2-80554 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-157SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-164SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-92156-25ul | |||
![SDS-Page: Recombinant Human BMAL1 Protein [H00000406-P01] - 12.5% SDS-PAGE Stained with Coomassie Blue.](http://images.novusbio.com/fullsize/Recombinant-Human-BMAL1-Protein-SDS-Page-H00000406-P01-img0002.jpg "SDS-Page: Recombinant Human BMAL1 Protein [H00000406-P01] - 12.5% SDS-PAGE Stained with Coomassie Blue.")
![Immunocytochemistry/Immunofluorescence: Lgr5/GPR49 Antibody [NBP1-28904] - Hek293 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Lgr5/GPR49 Antibody NBP1-28904 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Lgr5-GPR49-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-28904-img0009.jpg "Immunocytochemistry/Immunofluorescence: Lgr5/GPR49 Antibody [NBP1-28904] - Hek293 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Lgr5/GPR49 Antibody NBP1-28904 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunohistochemistry: Lgr5/GPR49 Antibody [NBP1-28904] - Wnt-related genes show selective expression in the ZG of human adrenal. IHC localization of LGR5 in the ZG. IHC was performed on formalin-fixed, paraffin-embedded human adrenal sections (4 um) using a chromogen-based detection system (3,3'-Diaminobenzidine), which results in a positive brown staining. Pictures are representative of six normal adrenal sections that were used in our microarray study; four from primary hyperaldosteronism patients and two from pheochromocytoma patients. Scale bar, 500 um (low power) and 100 um (high power). C, capsule. Image collected and cropped by CiteAb from the following publication (//academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-1734), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Lgr5-GPR49-Antibody-Immunohistochemistry-NBP1-28904-img0011.jpg)
![Immunohistochemistry: Lgr5/GPR49 Antibody [NBP1-28904] - Analysis of human small intestine.](http://images.novusbio.com/fullsize/Lgr5-GPR49-Antibody-Immunohistochemistry-NBP1-28904-img0005.jpg)
![Immunohistochemistry-Paraffin: Lgr5/GPR49 Antibody - BSA Free [NBP1-28904] - Wnt-related genes show selective expression in the ZG of human adrenal. A, Heat map of 37 genes (shown on the vertical axis), which are 5-fold or greater differentially expressed in ZG & ZF. Genes previously associated with the Wnt signaling pathway are highlighted in red. On the horizontal axis, each pair of ZG & ZF from the 20 adrenals are anonymized & numbered. Probe set & detailed microarray information are available from the National Center for Biotechnology Information Gene Expression Omnibus under accession number GSE64957. B, IHC localization of LGR5 & downstream Wnt signaling proteins in the ZG: from the canonical beta -catenin pathway, beta -catenin & LEF1, & from the noncanonical AP1/JUN pathway, c-JUN & p-c-JUN. IHC was performed on formalin-fixed, paraffin-embedded human adrenal sections (4 μm) using a chromogen-based detection system (3,3'-Diaminobenzidine), which results in a positive brown staining. Interestingly, beta -catenin staining was mostly membranous or cytoplasmic (rather than nuclear staining as highlighted by the arrows), indicating limited canonical Wnt activation. Pictures are representative of six normal adrenal sections that were used in our microarray study; four from primary hyperaldosteronism patients & two from pheochromocytoma patients. Scale bar, 500 μm (low power) & 100 μm (high power). C, capsule. Image collected & cropped by CiteAb from the following publication (//academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-1734), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-28904_rabbit-polyclonal-lgr5-gpr49-antibody-31020241618943.jpg)
![Immunohistochemistry: Neuropeptide Y Antibody [NBP1-46535] - Low magnification images showing the double staining pattern of NHE1 with neuropeptide NPY. Scale bar: 100um. Insets: High magnification images showing individual cells with double staining. Scale bar: 10um. Asterisks mark Hoechst-stained nuclei. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41598-019-42872-w), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Neuropeptide-Y-Antibody-Immunohistochemistry-NBP1-46535-img0001.jpg "Immunohistochemistry: Neuropeptide Y Antibody [NBP1-46535] - Low magnification images showing the double staining pattern of NHE1 with neuropeptide NPY. Scale bar: 100um. Insets: High magnification images showing individual cells with double staining. Scale bar: 10um. Asterisks mark Hoechst-stained nuclei. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41598-019-42872-w), licensed under a CC-BY license.")
![Immunocytochemistry/ Immunofluorescence: Neuropeptide Y Antibody [NBP1-46535] - NHE1 distribution (A) & colocalisation with markers for specific cell types (B–D) & major inputs (E, F, G). (A) NHE1 immunoreactivity is distributed throughout the rostrocaudal axis of the SCN (encircled by the dotted lines). Scale bar: 200 µm. OC: optic chiasm. 3 V: third ventricle. (B–G1) Low magnification images showing the double staining pattern of NHE1 with neuropeptides NP2 (B), GRP (C), & VIP (D) as well as markers for afferent inputs vGluT2 (E), NPY (F), & SERT (G1). Scale bar: 100 µm. Insets: High magnification images showing individual cells with double staining. Scale bar: 10 µm. Asterisks mark Hoechst-stained nuclei. (G2) High magnification image showing high degree of colocalisation (yellow) between NHE1 (green) & SERT (red). Scale bar: 10 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31015514), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-46535_goat-polyclonal-neuropeptide-y-antibody-310202416161848.jpg)
![Western Blot: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Melatonin Receptor 1B Antibody [NLS932] - Analysis for collagen I, fibronectin, and Alpha-smooth muscle actin (Alpha-SMA). Cells were treated with TGF-B1 (5 ng/mL) for 24 h after preincubation with Veh or Mel (0.1 mM or 1 mM) for 30 min. The graphs show the results of quantitative analysis of collagen I. Melatonin Prevents Transforming Growth Factor-B1 Stimulated Transdifferentiation of Renal Interstitial Fibroblasts to Myofibroblasts by Suppressing Reactive Oxygen Species-Dependent Mechanisms. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906396/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Western-Blot-NLS932-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Melatonin Receptor 1B Antibody [NLS932] - Analysis for collagen I, fibronectin, and Alpha-smooth muscle actin (Alpha-SMA). Cells were treated with TGF-B1 (5 ng/mL) for 24 h after preincubation with Veh or Mel (0.1 mM or 1 mM) for 30 min. The graphs show the results of quantitative analysis of collagen I. Melatonin Prevents Transforming Growth Factor-B1 Stimulated Transdifferentiation of Renal Interstitial Fibroblasts to Myofibroblasts by Suppressing Reactive Oxygen Species-Dependent Mechanisms. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906396/) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Melatonin receptor type 1 B (MTR1B) in rat tissues fixed in paraformaldehyde and embedded in paraffin. A,B-brain, C-prostate. Image from verified customer review.](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Immunohistochemistry-Paraffin-NLS932-img0008.jpg)
![Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. Short-term diabetic treated with MLT (MD1) Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions. J Diabetes Res (2015)](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Immunohistochemistry-Paraffin-NLS932-img0009.jpg)
![Western Blot: Melatonin Receptor 1B Antibody [NLS932] - Analysis of 1) HepG2 and 2) A431.](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Western-Blot-NLS932-img0003.jpg)
![Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. Short-term control (C1). Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions. J Diabetes Res (2015)](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Immunohistochemistry-Paraffin-NLS932-img0011.jpg)
![Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Analysis of Human Brain. 8 ug/ ml.](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Immunohistochemistry-Paraffin-NLS932-img0006.jpg)
![Immunohistochemistry: Melatonin Receptor 1B Antibody [NLS932] - Analysis of Human Brain using Fast Red with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Immunohistochemistry-NLS932-img0004.jpg)
![Immunohistochemistry: Melatonin Receptor 1B Antibody [NLS932] - Staining of Mouse Brain.](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Immunohistochemistry-NLS932-img0005.jpg)
![Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. Short-term control treated with MLT (M1). Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions. J Diabetes Res (2015)](http://images.novusbio.com/fullsize/Melatonin-Receptor-1B-Antibody-Immunohistochemistry-Paraffin-NLS932-img0010.jpg)
![Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls932_rabbit-polyclonal-melatonin-receptor-1b-antibody-310202416114744.jpg)
![Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls932_rabbit-polyclonal-melatonin-receptor-1b-antibody-310202416114737.jpg)
![Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls932_rabbit-polyclonal-melatonin-receptor-1b-antibody-310202416121978.jpg)
![Western Blot: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Effects of luzindole on inhibitory action of melatonin on TGF-beta 1-stimulated proliferation & activation in renal interstitial fibroblasts. (A) Reverse transcription-polymerase chain reaction analysis of melatonin receptor type 1A (MT1) & type 1B (MT2) in NRK-49F cells. (B) NRK-49F cells were treated with with TGF-beta 1 (5 ng/mL) after preincubation with vehicle (Veh) or melatonin (Mel; 1mM) in the presence or absence of luzindole (Luz; 100 μM) for 30 min. Cell viability was assessed using CCK-8 assay at 0, 24, & 48 h. The OD was measured at 450 nm. (C) Western blot analysis for alpha -SMA & p-Smad2/3. Cells were treated with TGF-beta 1 (5 ng/mL) for 24 h after preincubation with Veh or Mel (1 mM) in the presence or absence of luzindole (Luz; 20 μM or 100 μM) for 30 min. The graphs show the results of quantitative analysis of alpha -SMA (D) & p-Smad2/3 (E). ** p < 0.01 & *** p < 0.001 vs. Veh-treated cells. #p < 0.05 vs. TGF-beta 1-treated cells. NS: not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906396), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls932_rabbit-polyclonal-melatonin-receptor-1b-antibody-3102024161367.jpg)
![Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls932_rabbit-polyclonal-melatonin-receptor-1b-antibody-310202416121951.jpg)
![Western Blot: TRPM2 Antibody [NB110-81601] - Lane 1: CHO cells untransfected. Lane 2: CHO cell transfected with rat TRPM2 Lane 3: Mouse cortical neurons (cultured) Photo courtesy of Dr. Paco Herson, Oregon Health & Science University.](http://images.novusbio.com/fullsize/TRPM2-Antibody-Western-Blot-NB110-81601-img0007.jpg "Western Blot: TRPM2 Antibody [NB110-81601] - Lane 1: CHO cells untransfected. Lane 2: CHO cell transfected with rat TRPM2 Lane 3: Mouse cortical neurons (cultured) Photo courtesy of Dr. Paco Herson, Oregon Health & Science University.")
![Immunocytochemistry/Immunofluorescence: TRPM2 Antibody [NB110-81601] - Neuro2a cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-TRPM2 at 5 ug/mL overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TRPM2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-81601-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: TRPM2 Antibody [NB110-81601] - Staining of rat hippocampus using NB110-81601. TRPM2 is stained red, GFAP is stained green and nuclei staining is blue. Photo courtesy of Dr. Ji-Zhong Bai, The University of Auckland, New Zealand.](http://images.novusbio.com/fullsize/TRPM2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-81601-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TRPM2 Antibody [NB110-81601] - TRPM2 antibody was tested in Neuro2A cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/TRPM2-Antibody-Immunocytochemistry-Immunofluorescence-NB110-81601-img0009.jpg)
![Western Blot: ABCA1 Antibody (HJ1) [NB100-2068] - Detection of ABCA1 in wildtype liver tissue (in RIPA) Lane 1: KO mouse liver tissue. Lane 2: WT mouse liver tissue.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Western-Blot-NB100-2068-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: ABCA1 Antibody (HJ1) [NB100-2068] - Detection of ABCA1 in wildtype liver tissue (in RIPA) Lane 1: KO mouse liver tissue. Lane 2: WT mouse liver tissue.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: ABCA1 Antibody (HJ1) [NB100-2068] - Analysis of ABCA1 in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Immunohistochemistry-NB100-2068-img0006.jpg)
![Flow Cytometry: ABCA1 Antibody (HJ1) [NB100-2068] - Staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using ABCA1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Flow-Cytometry-NB100-2068-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Somatostatin R2/SSTR2 Antibody [NB300-157] - U2OS cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with antibody at 1:50 overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Somatostatin-R2-SSTR2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-157-img0005.jpg "Immunocytochemistry/Immunofluorescence: Somatostatin R2/SSTR2 Antibody [NB300-157] - U2OS cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with antibody at 1:50 overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: Somatostatin R2/SSTR2 Antibody [NB300-157] - Staining of Somatostatin Receptor 2 in mouse pancreas using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Somatostatin-Receptor-2-Antibody-Immunohistochemistry-Paraffin-NB300-157-img0004.jpg)
![Immunohistochemistry-Paraffin: Somatostatin R2/SSTR2 Antibody [NB300-157] - Staining of paraffin embedded rat pancreas tissue.](http://images.novusbio.com/fullsize/Somatostatin-Receptor-2-Antibody-Immunohistochemistry-Paraffin-NB300-157-img0003.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Western blot analysis of lipid transporters in macrophages treated with or without oxLDL using antibodies against ABCA1 (NB400-164), SR-B1 (NB400-104), and CD36 (NB400-144) . Lrp1Y63F impairs Abca1-mediated cholesterol efflux and increases lipid accumulation in macrophages. Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29292) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Western-Blot-NB400-164-img0008.jpg "<b>Biological Strategies Validation. </b>Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Western blot analysis of lipid transporters in macrophages treated with or without oxLDL using antibodies against ABCA1 (NB400-164), SR-B1 (NB400-104), and CD36 (NB400-144) . Lrp1Y63F impairs Abca1-mediated cholesterol efflux and increases lipid accumulation in macrophages. Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29292) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: ABCA1 Antibody (3A1.891.3) [NB400-164] - Analysis of FFPE mouse liver using ABCA1 antibody at 1:500 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Plasma membrane staining was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Immunohistochemistry-Paraffin-NB400-164-img0007.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Detection of ABCA1 using NB400-164 at various dilutions in ABCA1 transfected HeLa lysates.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Western-Blot-NB400-164-img0004.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Analysis of ABCA1 in (A) T09 treated RAW 264.7 cells and (B) untreated RAW 264.7 cells.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Western-Blot-NB400-164-img0006.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F mutation downregulates hepatic Abca1 levels.(A) Western blot analysis of Abca1 expression in the liver from Lrp1Y63F;Ldlr−/− & Ldlr−/− mice fed with HCHF diet for 16 weeks (n = 5, each group). (B) Western blot analysis of Abca1 expression in the liver from 16 week HCHF-fed Lrp1Y63F;Ldlr−/− & Ldlr−/− mice after BMT (n = 5, each group). All data are mean ±SEM. **p<0.01. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-31020241535616.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F mutation has no effect on atherogenic signaling pathways & morphological phenotype in SMCs.(A) Left: representative images of H&E stained descending thoracic aortas (scale bar = 50 μm). Right: aortic wall thickness & cell number were quantified for the indicated genotypes. Data are expressed mean ±SEM; n = 3 per group & genotype. (B) HCHF diet in Lrp1Y63F;Ldlr−/− mice has no effect on PDGF & TGF beta -mediated signaling in the aorta. Proteins were extracted from whole aorta in Lrp1Y63F;Ldlr−/− & Ldlr−/− mice fed with indicated diets. Expression of proteins involved in PDGF signaling pathways was determined by Western blot analysis. (C) Lrp1Y63F mutation did not affect atherogenic signaling pathways mediated by PDGF in vitro. Primary SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB for 10 min. Expression of proteins involved in PDGF signaling were determined by Western blot analysis. (D) Lrp1Y63F mutation did not alter SMC functions in vitro. Primary cultured SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB under indicated conditions, then cell migration (left) & proliferation (right) were determined. Values from three independent experiments are expressed as mean ±SEM. *p<0.05. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-310202416175236.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F impairs Abca1 induction through inhibiting the PPAR gamma /LXR pathway.(A) Real-time PCR analysis of Abca1, Abca7, Pparg, Nr1h3 & Nr2h2 expression in macrophages treated with or without ox-LDL. (B–E) Isolated peritoneal macrophages from Lrp1Y63F;Ldlr−/− & Ldlr−/− were pre-incubated for 1 hr with (B) T0070907 (PPAR gamma antagonist, 10 μM), (C) Rosiglitizone (PPAR gamma agonist) at indicated concentrations in μM, (D) T0901317 (nonspecific LXR agonist) at indicated concentrations in μM, (E) LXR623 (LXR beta full agonist & LXR alpha partial agonist) at indicated concentrations in μM, followed by the treatment with or without oxLDL for an additional 24 hr. Abca1 expression was assessed by immunoblot analysis (left). Protein expression was quantified & analyzed (right). Data are mean ±SEM from three independent experiments. *p<0.05; **p<0.01. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-310202416154639.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F mutation has no effect on atherogenic signaling pathways & morphological phenotype in SMCs.(A) Left: representative images of H&E stained descending thoracic aortas (scale bar = 50 μm). Right: aortic wall thickness & cell number were quantified for the indicated genotypes. Data are expressed mean ±SEM; n = 3 per group & genotype. (B) HCHF diet in Lrp1Y63F;Ldlr−/− mice has no effect on PDGF & TGF beta -mediated signaling in the aorta. Proteins were extracted from whole aorta in Lrp1Y63F;Ldlr−/− & Ldlr−/− mice fed with indicated diets. Expression of proteins involved in PDGF signaling pathways was determined by Western blot analysis. (C) Lrp1Y63F mutation did not affect atherogenic signaling pathways mediated by PDGF in vitro. Primary SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB for 10 min. Expression of proteins involved in PDGF signaling were determined by Western blot analysis. (D) Lrp1Y63F mutation did not alter SMC functions in vitro. Primary cultured SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB under indicated conditions, then cell migration (left) & proliferation (right) were determined. Values from three independent experiments are expressed as mean ±SEM. *p<0.05. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-31020241616063.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Analysis in human cerebral cortex and liver tissues. Corresponding Myosin 5a RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0011.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Analysis in human cerebral cortex and liver tissues. Corresponding Myosin 5a RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Myosin 5a Antibody [NBP1-92156] - Staining of human cell line A-431 shows localization to microtubule organizing center & focal adhesion sites. Antibody staining shown in green.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-92156-img0005.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human kIdney shows moderate memberanous positivity in cells in tubules.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0013.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human cerebellum shows strong cytoplasmic positivity in Purkinje cells.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0002.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human cerebral cortex shows strong membranous positivity in neuropil.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0006.jpg)
![Immunohistochemistry-Paraffin: Myosin 5a Antibody [NBP1-92156] - Staining of human hippocampus shows strong cytoplasmic positivity in pyramidal cells.](http://images.novusbio.com/fullsize/Myosin-5a-Antibody-Immunohistochemistry-Paraffin-NBP1-92156-img0009.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - The MW of GPR30 is estimated to be 42 kDa, but higher MW sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and reprobed for b-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by b-actin, then normalizing to HBEC2-KT in each blot. Image collected and cropped by CiteAb from the following publication (biomedcentral.com/1471-2407/12/624), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Western-Blot-NBP1-31239-img0012.jpg "Western Blot: GPER/GPR30 Antibody [NBP1-31239] - The MW of GPR30 is estimated to be 42 kDa, but higher MW sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and reprobed for b-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by b-actin, then normalizing to HBEC2-KT in each blot. Image collected and cropped by CiteAb from the following publication (biomedcentral.com/1471-2407/12/624), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: GPER/GPR30 Antibody [NBP1-31239] - Detection of GPER/GPR30 in HUVEC nucleus. Image courtesy of a product review by Dr. Subhadeep Chakrabarti of University of Alberta.](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31239-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: GPER/GPR30 Antibody [NBP1-31239] - A. 50 ug 293T whole cell lysate/extract. B. 50 ug whole cell lysate/extract of GFP-human GPR30-transfected 293T cells (No boiling). C. 50 ug whole cell lysate/extract of GFP-human GPR30 and GPR30 siRNA-transfected 293T cells (No boiling). 5 % SDS-PAGE GPR30 antibody ) dilution: 1:1000](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Western-Blot-NBP1-31239-img0011.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - AhR & GPR30 receptors are present & functional in the MCF10AT1 cells. (A) RT-qPCR analysis of AhR & GPR30 mRNA expression levels represented in arbitrary units (a.u.) in the MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. Values represent mean ± SD of three independent experiments conducted in triplicate. (B) Representative Western blot analyses from three independent experiments of AhR & GPR30 protein expression in MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. (C) XRE-luciferase activity following 8 h exposure of MCF10AT1 cells to ITE at the indicated concentrations. TCDD 10−7 M was used as a control & results were expressed as % of TCDD 10−7 M activity. ***p < 0.001 in Student t-test. (D) XRE-luciferase activity upon 8 h of exposure to ITE 10−10 M alone or in combination with GNF351 at the indicated concentrations. TCDD 10−7 M was used as a control, & results were expressed as % of TCDD 10−7 M activity. Student t-tests revealed the statistically significant differences between unexposed & exposed cells: ***p < 0.001; & between ITE & ITE+GNF351: ###p < 0.001. Values in (C,D) represent mean ± SD of three independent experiments. (E) Representative Western blot analyses from three independent experiments of the phospho-MAPK/MAPK ratio upon exposure of MCF10AT1 cells to G1 (GPR30 agonist) for the times indicated, in the presence or absence of a 2 h pre-treatment with G15 (GPR30 antagonist). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416171440.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416173515.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Human endothelial cells express GPR30 protein in the cell nucleus.(A) Confluent monolayers of HUVECs from 3 different cords were lysed & the protein lysates were immunoblotted for GPR30. alpha -tubulin was used as loading control. (B) HUVEC monolayers at 30–40% confluence were treated with 40 nM siRNA (control or GPR30_4) for 48 hours prior to lysis followed by immunoblotting of the cell lysates for GPR30. alpha -tubulin was used as loading control. Data shown are mean ± SEM of 4 independent experiments. ** & ## indicate p<0.01 compared to untreated & control siRNA-treated cells, respectively. (C) Confluent HUVECs grown on glass coverslips were fixed, permeabilized & immunostained with anti-GPR30 antibody. Nuclei were stained with Hoechst33342 dye. The merged image shows GPR30 (red) & nuclei (blue) in pseudocolor. Representative images from 3 independent experiments are shown. Bar, 20 µm. (D) Confluent HUVECs were lysed & fractionated into cytosolic (C) & nuclear (N) fractions prior to western blotting for eNOS, GPR30, p65, alpha -tubulin & c-Jun. A representative set of images (obtained from different membranes) from 3 independent experiments is shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23285008), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416175294.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416173516.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416163721.jpg)
![Flow Cytometry: PGC1 alpha Antibody [NB100-60955] - Flow cytometric analysis of paraformaldehyde fixed HeLa cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nb100-60955_goat-polyclonal-pgc1-alpha-antibody-imgenex-img-30341-16520239183346.jpg "Flow Cytometry: PGC1 alpha Antibody [NB100-60955] - Flow cytometric analysis of paraformaldehyde fixed HeLa cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.")
![Immunohistochemistry-Paraffin: PGC1 alpha Antibody [NB100-60955] - Negative Control showing staining of paraffin embedded Human Kidney, with no primary antibody.](http://images.novusbio.com/fullsize/nb100-60955_goat-polyclonal-pgc1-alpha-antibody-imgenex-img-30341-1652023918336.jpg)
![Immunocytochemistry/Immunofluorescence: PGC1 alpha Antibody [NB100-60955] - Immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/nb100-60955_goat-polyclonal-pgc1-alpha-antibody-imgenex-img-30341-16520239183311.jpg)
![Immunocytochemistry/Immunofluorescence: PGC1 alpha Antibody [NB100-60955] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/nb100-60955_goat-polyclonal-pgc1-alpha-antibody-imgenex-img-30341-1652023918331.jpg)
![Immunohistochemistry-Paraffin: PGC1 alpha Antibody [NB100-60955] - (6ug/ml) staining of paraffin embedded Human Kidney. Heat induced antigen retrieval with citrate buffer pH 6, HRP-staining.](http://images.novusbio.com/fullsize/nb100-60955_goat-polyclonal-pgc1-alpha-antibody-imgenex-img-30341-16520239183335.jpg)
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of Lactate Dehydrogenase on different lysates with Rabbit anti-Lactate Dehydrogenase antibody at 1/1,000 dilution. Lane 1: Hela cell lysate Lane 2: A549 cell lysate Lane 3: MCF-7 cell lysate Lysates/proteins at 10 ug/Lane. Predicted band size: 37 kDa Observed band size: 37 kDa Exposure time: 1 minute; 10% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody at 1/1,000 dilution was used in 5% NFDM/TBST at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:300,000 dilution was used for 1 hour at room temperature.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Western-Blot-NBP2-67483-img0013.jpg "Western Blot: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of Lactate Dehydrogenase on different lysates with Rabbit anti-Lactate Dehydrogenase antibody at 1/1,000 dilution. Lane 1: Hela cell lysate Lane 2: A549 cell lysate Lane 3: MCF-7 cell lysate Lysates/proteins at 10 ug/Lane. Predicted band size: 37 kDa Observed band size: 37 kDa Exposure time: 1 minute; 10% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody at 1/1,000 dilution was used in 5% NFDM/TBST at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:300,000 dilution was used for 1 hour at room temperature.")
![Immunocytochemistry/Immunofluorescence: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of LOVO cells labeling Lactate Dehydrogenase with Rabbit anti-Lactate Dehydrogenase A/LDHA antibody (permeabilized with 0.05% Triton X-100 in PBS for 20 minutes, and then blocked with 2% negative goat serum for 30 minutes at room temperature. Cells were then incubated with Rabbit anti-Lactate Dehydrogenase antibody was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. Nuclear DNA was labelled in blue with DAPI.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunocytochemistry-Immunofluorescence-NBP2-67483-img0014.jpg)
![Immunohistochemistry-Paraffin: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of paraffin-embedded human breast carcinoma tissue with Rabbit anti-Lactate Dehydrogenase antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunohistochemistry-Paraffin-NBP2-67483-img0015.jpg)
![Flow Cytometry: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of Hela cells with Lactate Dehydrogenase antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Flow-Cytometry-NBP2-67483-img0001.jpg)
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Western blot analysis of Lactate Dehydrogenase on hybrid fish (crucian-carp) brain tissue lysate using anti-Lactate Dehydrogenase antibody at 1/500 dilution.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Western-Blot-NBP2-67483-img0011.jpg)
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Western blot analysis of Lactate Dehydrogenase A/LDHA on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Western-Blot-NBP2-67483-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Staining Lactate Dehydrogenase in A431 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunocytochemistry-Immunofluorescence-NBP2-67483-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Staining Lactate Dehydrogenase in A549 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunocytochemistry-Immunofluorescence-NBP2-67483-img0003.jpg)
![Immunohistochemistry-Paraffin: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of paraffin-embedded human breast carcinoma tissue using anti-Lactate Dehydrogenase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunohistochemistry-Paraffin-NBP2-67483-img0004.jpg)
![Immunohistochemistry-Paraffin: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of paraffin-embedded human liver cancer tissue using anti-Lactate Dehydrogenase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunohistochemistry-Paraffin-NBP2-67483-img0005.jpg)
![Immunohistochemistry-Paraffin: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of paraffin-embedded human liver tissue using anti-Lactate Dehydrogenase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunohistochemistry-Paraffin-NBP2-67483-img0006.jpg)
![Immunohistochemistry-Paraffin: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of paraffin-embedded mouse liver tissue using anti-Lactate Dehydrogenase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunohistochemistry-Paraffin-NBP2-67483-img0007.jpg)
![Immunohistochemistry-Paraffin: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of paraffin-embedded mouse skeletal muscle tissue using anti-Lactate Dehydrogenase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunohistochemistry-Paraffin-NBP2-67483-img0008.jpg)
![Immunohistochemistry-Paraffin: Lactate Dehydrogenase A/LDHA Antibody (SU39-06) [NBP2-67483] - Analysis of paraffin-embedded mouse testis tissue using anti-Lactate Dehydrogenase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody-SU39-06-Immunohistochemistry-Paraffin-NBP2-67483-img0009.jpg)